ReviewJournal of neuro-oncology2015
The role of STAT3 in tumor-mediated immune suppression.
Review in Journal of neuro-oncology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 70 citations in OpenAlex.
- Within and beyond the tumor: Mechanisms of glioblastoma-induced immunosuppression.Neuro-oncology advances · 2025Review
- Investigative needle core biopsies support multimodal deep-data generation in glioblastoma.Nature communications · 2025Article
- Interleukin 6 and cancer resistance in glioblastoma multiforme.Neurosurgical review · 2024Review
- STING agonist 8803 reprograms the immune microenvironment and increases survival in preclinical models of glioblastoma.The Journal of clinical investigation · 2024Article
- Article
- PD-1 and PD-L1 inhibitors in cold colorectal cancer: challenges and strategies.Cancer immunology, immunotherapy : CII · 2023Review
- Signaling pathways in brain tumors and therapeutic interventions.Signal transduction and targeted therapy · 2023Review
- Next Steps for Immunotherapy in Glioblastoma.Cancers · 2022Review
- Translational landscape of glioblastoma immunotherapy for physicians: guiding clinical practice with basic scientific evidence.Journal of hematology & oncology · 2022Review
- Glioma-targeted delivery of exosome-encapsulated antisense oligonucleotides using neural stem cells.Molecular therapy. Nucleic acids · 2022Article
- Review
- Neuroimmunomodulatory Properties of Flavonoids and Derivates: A Potential Action as Adjuvants for the Treatment of Glioblastoma.Pharmaceutics · 2022Review
- Insulin/IGF-1 signaling promotes immunosuppression via the STAT3 pathway: impact on the aging process and age-related diseases.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2021Review
- Aberrant Rac pathway signalling in glioblastoma.Small GTPases · 2021Review
- Targeting STAT3 with Proteolysis Targeting Chimeras and Next-Generation Antisense Oligonucleotides.Molecular cancer therapeutics · 2021Review
- Innovative Approaches in the Battle Against Cancer Recurrence: Novel Strategies to Combat Dormant Disseminated Tumor Cells.Frontiers in oncology · 2021Review
- Immune Modulatory Short Noncoding RNAs Targeting the Glioblastoma Microenvironment.Frontiers in oncology · 2021Review
- MicroRNA‑19b inhibitors can attenuate the STAT3 signaling pathway in NPC C666‑1 cells.Molecular medicine reports · 2020Article
- Loss of BAP1 expression is associated with an immunosuppressive microenvironment in uveal melanoma, with implications for immunotherapy development.The Journal of pathology · 2020Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
The role of tumor-induced immune modulation in cancer progression is currently a focus of investigation. The signal transducer and activator of transcription 3 (STAT3) is an established molecular hub of immunosuppression, and its signaling pathways are classically overactivated within malignancies. This article will review STAT3 operational mechanisms within the immune system and the tumor microenvironment, with a focus on therapeutic strategies that may impact outcomes for patients with cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.